OpenEvidence weighs $200M funding round at $20B valuation: Report

OpenEvidence, a company specializing in artificial intelligence for healthcare documentation, mulled a $200 million funding round valuing the firm at a staggering $20 billion but appears to have shelved the plan due to concerns over share dilution for founders and existing investors. This move highlights the company's ambitious growth trajectory and the complexities of maintaining shareholder value amidst rapid scaling. With acquisition talks also on the table, the company's strategic direction could significantly reshape the healthcare IT landscape, underscoring the intense competition and high stakes in the AI sector.